Ongoing advancements in nanotechnology have enabled the fabrication of biomimetic nanoparticles to deliver STING agonists directly to static and distinct metastatic tumour cells, thereby activating innate immunological pathways, suppressing immune evasion and enhancing the cytotoxicity. The gene discussed is STING1; the disease is neoplasm.